There is disclosed a polypeptide that specifically binds TL1A, DR3, CD30, or CD30L for use in treating any of an inflammatory lung disease, a progressive autoimmune neuropathy, or for use in polarizing a T cell response to Th1 or Th2 in a subject, modulating IL-13 production in a subject or modulating MMP9 production in a subject.